publication date: Jan. 17, 2014


In another round of changes in the executive suite at MD Anderson Cancer Center, Dan Fontaine was appointed head the institutional advancement division, President Ronald DePinho announced in an email to the faculty and staff.

As he leaves the job of senior vice president for business affairs, he will retain some of the functions he has previously supervised in the newly created role of executive chief of staff.

In the email dated Jan. 16, DePinho wrote that “Dan will retain oversight of business development (for MD Anderson Cancer Network, Moon Shots Program external business opportunities, technology-based ventures and strategic industry ventures), regulatory matters (compliance, legal services, internal audit, information security, UT Police), and, for institutional advancement, he’ll also provide oversight for the Children’s Art Project, communications, corporate alliances, development, marketing, physician relations, public education and volunteer services.

“In his new position Dan will report to me,” DePinho wrote.

Facilities management, finance, human resources, and information technology will remain under the leadership of Leon Leach, executive vice president and chief business officer.

“Leon will continue to report to me and provide final business review and recommendations for all transactions that affect our financial well-being. Leon and Dan respectively will remain chairman and vice chairman of MD Anderson Services Corp.,” DePinho wrote. “In addition to his other responsibilities, Leon has also agreed to provide leadership and coordination of the detailed development of our strategic framework, with participation and contribution to that effort from all areas of MD Anderson.”

The changes are part of a … Continue reading 40-03 MD Anderson Leadership Changes

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.